Roche notified European patients that it is terminating development of emugrobart—a Genentech‑originated antibody—for spinal muscular atrophy and facioscapulohumeral muscular dystrophy after trials failed to show consistent muscle growth or motor‑function benefit. Separately, Genentech publicly announced it was discontinuing a related muscle‑preserving program following an early Phase II analysis that indicated the candidate was unlikely to meet endpoints. The moves remove a high‑profile muscle‑growth approach from late‑stage pipelines and raise questions about translational risks for similar mechanisms being tested in obesity and other settings.